Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon β2-1b

Multiple Sclerosis

Volumn 16, Issue 1, 2010, Pages 30-38

  Jensen, Mark A ^a   Yanowitch, Rachel N ^a   Reder, Anthony T ^a   White, David M ^a   Arnason, Barry Gw ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Beta interferon; Immunology; Multiple sclerosis; Relapsing remitting

Indexed keywords

B7 ANTIGEN; BETA1A INTERFERON; CD14 ANTIGEN; CD86 ANTIGEN; GLATIRAMER; IMMUNOGLOBULIN LIKE TRANSCRIPT 3; IMMUNOGLOBULIN LIKE TRANSCRIPT 4; INTERFERON BETA SERINE; MEMBRANE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL INTERACTION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; RELAPSE; REMISSION; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGENS, CD80; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC; RECURRENCE; T-LYMPHOCYTES;

EID: 73949121806     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509352794     Document Type: Article

References (34)

1. Borges L., Cosman D. LIRs/ILTs/MIRs, inhibitory and stimulatory Ig-superfamily receptors expressed in myeloid and lymphoid cells. Cytokine Growth Factor Rev 2000 ; 11: 209-217.
2. Dietrich J., Nakajima H., Colonna M. Human inhibitory and activating Ig-like receptors which modulate the function of myeloid cells. Microbes Infect 2000 ; 2: 323-329. (Pubitemid 30167667)
3. Cella M., Dohring C., Samaridis J., et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 1997 ; 185: 1743-1751.
4. Manavalan JS, Kim-Schulze S., Scotto L., et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004 ; 16: 1055-1068.
5. Kim-Schulze S., Seki T., Vlad G., et al. Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells. Am J Transplant 2006 ; 6: 76-82.
6. Gleissner CA, Zastrow A., Klingenberg R., et al. IL-10 inhibits endothelium-dependent T cell costimulation by up-regulation of ILT3/4 in human vascular endothelial cells. Eur J Immunol 2007 ; 37: 177-192.
7. Chang CC, Ciubotariu R., Manavalan JS, et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002 ; 3: 237-243.
8. Kim-Schulze S., Scotto L., Vlad G., et al. Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells. J Immunol 2006 ; 176: 2790-2798.
9. Antel JP, Arnason BG, Medof ME Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 1979 ; 5: 338-342.
10. Karaszewski JW, Reder AT, Anlar B., Arnason GW Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J Neuroimmunol 1993 ; 43: 1-7.
11. Arnason BG, Toscas A., Dayal A., Qu Z., Noronha A. Role of interferons in demyelinating diseases. J Neural Transm Suppl 1997 ; 49: 117-123.
12. Noronha A., Toscas A., Jensen MA Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990 ; 27: 207-210.
13. Karandikar NJ, Crawford MP, Yan X., et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 2002 ; 109: 641-649.
14. Tennakoon DK, Mehta RS, Ortega SB, Bhoj V., Racke MK, Karandikar NJ Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006 ; 176: 7119-7129.
15. Manavalan JS, Rossi PC, Vlad G., et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003 ; 11: 245-258.
16. Penna G., Roncari A., Amuchastegui S., et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+ Foxp3 + regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 2005 ; 106: 3490-3497.
17. Buckland M., Jago CB, Fazekasova H., et al. Aspirin-treated human -DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Am J Transplant 2006 ; 6: 2046-2059.
18. Svajger U., Vidmar A., Jeras M. Niflumic acid renders dendritic cells tolerogenic and up-regulates inhibitory molecules ILT3 and ILT4. Int Immunopharmacol 2008 ; 8: 997-1005.
19. Suciu-Foca N., Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 2007 ; 248: 59-67.
20. Colonna M., Samaridis J., Cella M., et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 1998 ; 160: 3096-3100.
21. Shiroishi M., Kuroki K., Rasubala L., et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/ LIR2/ILT4/CD85d). Proc Natl Acad Sci USA 2006 ; 103: 16412-16417.
22. Fainardi E., Rizzo R., Melchiorri L., et al. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings. J Neuroimmunol 2003 ; 142: 149-158.
23. Wiendl H., Feger U., Mittelbronn M., et al. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain 2005 ; 128: 2689-2704.
24. Mitsdoerffer M., Schreiner B., Kieseier BC, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 2005 ; 159: 155-164.
25. Feger U., Tolosa E., Huang YH, et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood 2007 ; 110: 568-577.
26. Liang S., Baibakov B., Horuzsko A. HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory receptor. Eur J Immunol 2002 ; 32: 2418-2426.
27. Ristich V., Liang S., Zhang W., Wu J., Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005 ; 35: 1133-1142.
28. Jensen MA, Yanowitch RN, White DM, and Arnason BG Multiple Sclerosis (MS): IFNβ2-1b Induces Expression of Immunoinhibitory Immunoglobulin-Like Transcript 3 (ILT3) on Myeloid Cells. Neurology 2009 ; 72 Number 11 (Suppl 3). A470.
29. Jensen MA, Yanowitch RN, White DM, and Arnason BG Immunoglobulin-like transcript 3 expression on circulating CD14+ cells is low in active remitting relapsing MultipleSclerosis and is induced by Interferon β2-1b. Mult Scler 2009 ; 15: 1406.
30. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127.
31. Suciu-Foca N., Feirt N., Zhang QY, et al. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol 2007 ; 178: 7432-7441.
32. Schreiner B., Mitsdoerffer M., Kieseier BC, et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004 ; 155: 172-182.
33. Marckmann S., Wiesemann E., Hilse R., Trebst C., Stangel M., Windhagen A. Interferon-betaup-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Clin Exp Immunol 2004 ; 138: 499-506.
34. Wiesemann E., Deb M., Trebst C., Hemmer B., Stangel M., Windhagen A. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. Mult Scler 2008 ; 14: 166-176.